Galux reports AI-designed antibodies for 8 targets, including PD-L1 and IL-11

Galux has unveiled another set of AI-designed antibodies, this time targeting eight proteins, as the Korean startup pushes its platform deeper into precision drug discovery.

The company said its GaluxDesign platform successfully produced antibodies against PD-L1, HER2, EGFR (S468R), ACVR2A/B, FZD7, ALK7, CD98hc and IL-11. The results build on six earlier targets reported in March and, according to Galux, show the system’s scalability and accuracy.

Among the highlights was IL-11, a protein tied to aging that had no prior antibody structures. Galux said its platform also separated closely related proteins that differ by only one or two amino acids, an indication of its potential to cut off-target effects.

The company pointed to its PD-L1 program as proof of precision. Using cryo-electron microscopy, researchers confirmed that an AI-designed antibody bound the protein in a novel way, with the experimental structure nearly identical to the computer model.

Galux is now extending its work to GPCRs and ion channels, and said it is working with pharma partners in Korea and abroad to move candidates into the clinic.